drugset / Trial / NCT07681596
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.
Timeline
- Start
- 2026-07-09
- Primary completion
- 2029-10-30
- Completion
- 2029-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD4045 | Cell therapy | — | — |
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | aldesleukin | Protein / enzyme biologic | — | — |